Commandez votre montre hebdomadaire Erasca, Inc.
Quantité totale PI	87
Rang # Quantité totale PI	15 555
Note d'activité PI	2,9/5.0    98
Rang # Activité PI	6 924
Symbole boursier	ERAS (nasdaq)
ISIN	US29479A1088
Capitalisation	856M  (USD)
Classe Nice dominante	Produits pharmaceutiques, vétéri...

Brevets Marques 22 4 12 3 43 0 3
Dernier brevet	2025 - Tricyclic pyridones and pyrimidones
Premier brevet	2020 - Tricyclic pyridones and pyrimidones
Dernière marque	2022 - ERASCA VENTURES
Première marque	2019 - ERASCA

Industrie (Classification de Nice)

Derniers inventions, produits et services 2025 Invention Kras inhibitors. The present embodiments provide compounds of Formula I, compositions of the comp... 2024 Invention Compositions and methods for treating cancer. The disclosure relates to methods of treating gliob... Invention Macrocyclic ulk1/2 inhibitors and their use thereof. Described herein are macrocycle compounds th... Invention Thiophene ulk1/2 inhibitors and their use thereof. Described herein are compounds that are ULK1/2... Invention Kras inhibitors. The present embodiments provide compounds of Formula (I), compositions of the co... Invention Raf inhibitor and erk1/2 and/or shp2 inhibitor combination therapy. A pharmaceutical combination ... Invention Raf inhibitor and kras g12c inhibitor combination therapy. A pharmaceutical combination including... 2023 Invention Erk1/2 inhibitor polymorph forms. Disclosed herein are polymorph forms of (S)-N-(2-amino-l-(3-chl... Invention Kras inhibitor conjugates. The present embodiments provide compounds of Formula I, compositions o... Invention Tricyclic pyridones and pyrimidones. Compounds with KRAS G12C inhibitory active are disclosed an... Invention Tricyclic pyridones and pyrimidones. Compounds with KRAS G12C inhibitory active are disclosed and... Invention Tricyclic pyrimidones. Compounds with KRAS G12C inhibitory active are disclosed and methods of us... Invention Antibodies against egfr and their uses. Described herein are antibodies that bind EGFR domain II... Invention Antibodies against egfr and their uses. Described herein are antibodies that bind EGFR domain II ... 2022 Invention Thiophene ulk1/2 inhibitors and their use thereof. Described herein are compounds that are ULK1/... Invention Uses of tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors. The pre... Invention Uses of tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors. The pres... Invention Egfr inhibitor polymorph forms. SNN-(3-bromo-2-fluorophenyl)-7-((4-methylpiperazin-1-yl)methyl)-7... Invention Jak inhibitor with erk1/2 and/or shp2 inhibitors combination therapy. The present invention rela... Invention Jak inhibitor with erk1/2 and/or shp2 inhibitors combination therapy. The present invention relat... Invention Selective kras inhibitors. The present embodiments provide compounds of Formula (I), compositions... Invention Erk1/2 and egfr inhibitors combination therapy. The present disclosure relates generally to the ... Invention Erk1/2 and shp2 inhibitors combination therapy. The present disclosure relates generally to the ... Invention Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancer. The present disclo... Invention Erk1/2 or shp2 inhibitors and flt3 inhibitors combination therapy. The present disclosure relate... Invention Erk1/2 and kras g12c inhibitors combination therapy. The present disclosure relates generally to... Invention Erk1/2 and egfr inhibitors combination therapy. The present disclosure relates generally to the u... Invention Erk1/2 or shp2 inhibitors and flt3 inhibitors combination therapy. The present disclosure relates... Invention Erk1/2 and shp2 inhibitors combination therapy. The present disclosure relates generally to the u... Invention Erk1/2 and kras g12c inhibitors combination therapy. The present disclosure relates generally to ... Invention Erk1/2 and cdk4/6 inhibitors combination therapy. The present disclosure relates generally to the... Invention Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancer. The present disclos... Invention Tricyclic kras inhibitors. The present embodiments provide compounds of Formula (I), compositions... Invention Tricyclic pyridones and pyrimidones. A compound of Formula (I) is provided: (I) where the variab... Invention Amide and urea-containing tricyclic kras inhibitors. The present embodiments provide compounds o... Invention Kras inhibitor conjugates. The present application provides conjugates of protein-binding ligand... Invention Amide and urea-containing tricyclic kras inhibitors. The present embodiments provide compounds of... Invention Uses of heterocyclic inhibitors of erk1/2. The use of heterocyclic inhibitors of ERK1/2 for trea... P/S venture capital services, namely, providing financing to entrepreneurs and emerging and start-up ... P/S philanthropic services, namely, providing charitable grants to others for use in environmental, s... 2021 Invention Combination therapies for the treatment of cancer. The present disclosure provides methods of tr... Invention Compositions and methods for treating cancer. The present disclosure relates to compounds that a... P/S Anti-cancer preparations; pharmaceutical and biological preparations for the treatment of cancer;... P/S Anti-cancer preparations; pharmaceutical preparations and substances for the treatment of cancer;... 2020 P/S Drug discovery services; pharmaceutical research and development; scientific research for medical... P/S Research and development in the fields of pharmaceuticals, cancer, and oncology treatments and cu...